NTLA logo

ARKK Holdings of NTLA

Intellia Therapeutics

Intellia Therapeutics is a biotechnology company focused on the development of therapies using CRISPR/Cas9 gene-editing technology to potentially treat genetic diseases. The company generates revenue through partnerships, collaborations, and the development of proprietary treatments aimed at commercializing innovative gene-editing solutions.

#29 in All Funds#17 in ARKG#25 in ARKK

Trades of NTLA in ARKK

The ten most recent trades of Intellia Therapeutics in the ARKK ETF.View all trades

Date
Direction
Market Value
% of Position
% of ETF
Jan 21, 2025Buy$676,5780.81%0.01%
Jan 10, 2025Buy$1,332,8531.46%0.02%
Jan 08, 2025Buy$898,5210.88%0.01%
Dec 20, 2024Buy$2,292,4862.28%0.04%
Dec 18, 2024Buy$921,2830.90%0.01%
Dec 16, 2024Buy$950,9730.89%0.01%
Dec 13, 2024Buy$574,3520.55%0.01%
Nov 19, 2024Buy$2,299,5932.07%0.04%
Nov 18, 2024Buy$1,655,7401.48%0.03%
Nov 15, 2024Buy$340,2930.30%0.01%